Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Safety of immune checkpoint inhibitor in urothelial cancer
Kelly K et al. Cancer. 2018 Feb 22. doi: 10.1002/cncr.31293.
Key clinical point: The immune checkpoint inhibitor avelumab appears to be well tolerated with a manageable safety profile.
Major finding: In all, 67% of patients had a treatment-related adverse event, and 10.2% had ones that were grade 3 or greater.
Study details: Safety analysis of pooled data on 1,738 patients treated with avelumab in a phase 1 and a phase 2 clinical trial.
Disclosures: The study was sponsored by Merck and part of an alliance between Merck and Pfizer. Dr. Kelly reported no conflicts of interest. Multiple coauthors reported research funding, consulting fees, honoraria, or other consideration from various companies, and several coauthors are Merck employees.
Source: Kelly K et al. Cancer. 2018 Feb 22. doi: 10.1002/cncr.31293.
Kelly K et al. Cancer. 2018 Feb 22. doi: 10.1002/cncr.31293.